Baxter International Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew Hider
- Full Time Employees
- 38,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- One Baxter Parkway Deerfield IL United States of America 60015
- IPO Date
- Oct 27, 1981
- CIK
- 0000010456
- Website
- baxter.com
- Similar Companies
- Business
- Baxter International Inc specializes in medical products and therapies, healthcare system technologies, and pharmaceuticals. The company's main products include advanced surgical technologies under its Advanced Surgery division, infusion therapies and intravenous delivery systems under Infusion Therapies and Technologies, and hospital pharmaceuticals focusing on pain management, critical care, anti-infection, and oncology. Its Healthcare Systems and Technologies segment operates through divisions such as Front Line Care, Digital Platform and Innovations, Care and Connectivity Solutions, and Global Services. Baxter serves healthcare providers globally, offering products used at the hospital bedside, operating rooms, intensive care units, home care, and alternate care settings. Founded in 1931 and headquartered in Deerfield, Illinois, Baxter operates worldwide and emphasizes innovation to improve patient outcomes and operational efficiency. Recently, Baxter has undergone significant strategic transformations including the spin-off of its Renal Care and Acute Therapies global business units to establish a separate publicly traded company, streamlining its commercial and manufacturing footprint to enhance business performance, and reviewing strategic alternatives for its BioPharma Solutions business. In 2025, the company appointed Andrew Hider as CEO to advance continuous improvement and sustainable growth. Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation connected patient monitoring device, and achieved recognition with a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative in categories including IV Solutions, Nutrition Solutions, and Premix Drugs. The company also completed the integration of its Hill-Rom acquisition and continues to focus on operational simplification by reducing distribution centers and enhancing digital health solutions. Baxter reported third-quarter 2025 sales growth driven by Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments with ongoing investments in R&D to support steady product launches and innovation.
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting
Baxter International Still Has A Path To Upside
Madison Small Cap Fund Q1 2026 Portfolio Activity
Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates
Baxter beats quarterly expectations on strong demand for medical devices
Is Baxter International (BAX) 53.0% Undervalued After Q1 2026 Earnings Beat? Adjusted EPS $0.36 vs $0.11 est; Revenue $2.70B vs $2.62B est -- GF Score 57/100
Baxter Reports First-Quarter 2026 Results
Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline
Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again?
Baxter International (NYSE:BAX) vs. GN Store Nord (OTCMKTS:GNNDY) Head-To-Head Analysis
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of “Hold” from Brokerages
Reviewing Zynex (NASDAQ:ZYXI) and Baxter International (NYSE:BAX)
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy